Gilead Sciences Q1 Earnings Beat Estimates_老虎社区_美港股上老虎

Gilead Sciences Q1 Earnings Beat Estimates

Zacks2021-04-30

Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

s3nGz
·2021-04-30
Nice
回复
点赞
举报
MoccaTB
·2021-04-30
Nice
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2131402534?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-30 05:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2131402534","market":"us","top_or_hot":-1,"title":"Gilead Sciences Q1 Earnings Beat Estimates","media":"Zacks","content":"<div>\n<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Q1 Earnings Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Q1 Earnings Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 05:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html","article_id":"2131402534","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2131402534","pubTimestamp":1619731509,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consen","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"吉利德科学第一季度盈利超过预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.97%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $2.15 per share when it actually produced earnings of $2.19, delivering a surprise of 1.86%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.42 billion for the quarter ended March 2021, missing the Zacks Consensus Estimate by 5.30%. This compares to year-ago revenues of $5.55 billion. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Gilead shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 11.4%.Gilead Sciences shares fell 2.73% in after-hour trading.What's Next for Gilead?While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.74 on $6.2 billion in revenues for the coming quarter and $7.22 on $24.94 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":103918632,"gmtCreate":1619742677026,"gmtModify":1634210289308,"author":{"id":"3571036752907389","authorId":"3571036752907389","authorIdStr":"3571036752907389","name":"s3nGz","avatar":"https://static.tigerbbs.com/c929cbe961a8fd811e48f9d875c5796c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571036752907389"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103918632","repostId":2131402534,"repostType":4,"repost":{"id":"2131402534","pubTimestamp":1619731509,"share":"https://www.laohu8.com/m/news/2131402534?lang=&edition=full","pubTime":"2021-04-30 05:25","market":"us","language":"en","title":"Gilead Sciences Q1 Earnings Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2131402534","media":"Zacks","summary":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consen","content":"<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.</p><p>This quarterly report represents an earnings surprise of 0.97%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $2.15 per share when it actually produced earnings of $2.19, delivering a surprise of 1.86%.</p><p>Over the last four quarters, the company has surpassed consensus EPS estimates three times.</p><p>Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.42 billion for the quarter ended March 2021, missing the Zacks Consensus Estimate by 5.30%. This compares to year-ago revenues of $5.55 billion. The company has topped consensus revenue estimates two times over the last four quarters.</p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p>Gilead shares have added about 10.6% since the beginning of the year versus the S&amp;P 500's gain of 11.4%.</p><p>Gilead Sciences shares fell 2.73%&nbsp;in&nbsp;after-hour trading.<img src=\"https://static.tigerbbs.com/0ced1f07fb72f566e12b80345577f2ca\" tg-width=\"1274\" tg-height=\"634\" referrerpolicy=\"no-referrer\"></p><p><b>What's Next for Gilead?</b></p><p>While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p>Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.74 on $6.2 billion in revenues for the coming quarter and $7.22 on $24.94 billion in revenues for the current fiscal year.</p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Q1 Earnings Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Q1 Earnings Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 05:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2131402534","content_text":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.97%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $2.15 per share when it actually produced earnings of $2.19, delivering a surprise of 1.86%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.42 billion for the quarter ended March 2021, missing the Zacks Consensus Estimate by 5.30%. This compares to year-ago revenues of $5.55 billion. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Gilead shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 11.4%.Gilead Sciences shares fell 2.73% in after-hour trading.What's Next for Gilead?While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.74 on $6.2 billion in revenues for the coming quarter and $7.22 on $24.94 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":103991692,"gmtCreate":1619741866416,"gmtModify":1634210304495,"author":{"id":"3580696609412947","authorId":"3580696609412947","authorIdStr":"3580696609412947","name":"MoccaTB","avatar":"https://static.tigerbbs.com/06bb70f2fd1d34bedd4d0aa721d27bb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3580696609412947"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103991692","repostId":2131402534,"repostType":4,"repost":{"id":"2131402534","pubTimestamp":1619731509,"share":"https://www.laohu8.com/m/news/2131402534?lang=&edition=full","pubTime":"2021-04-30 05:25","market":"us","language":"en","title":"Gilead Sciences Q1 Earnings Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2131402534","media":"Zacks","summary":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consen","content":"<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.</p><p>This quarterly report represents an earnings surprise of 0.97%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $2.15 per share when it actually produced earnings of $2.19, delivering a surprise of 1.86%.</p><p>Over the last four quarters, the company has surpassed consensus EPS estimates three times.</p><p>Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.42 billion for the quarter ended March 2021, missing the Zacks Consensus Estimate by 5.30%. This compares to year-ago revenues of $5.55 billion. The company has topped consensus revenue estimates two times over the last four quarters.</p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p>Gilead shares have added about 10.6% since the beginning of the year versus the S&amp;P 500's gain of 11.4%.</p><p>Gilead Sciences shares fell 2.73%&nbsp;in&nbsp;after-hour trading.<img src=\"https://static.tigerbbs.com/0ced1f07fb72f566e12b80345577f2ca\" tg-width=\"1274\" tg-height=\"634\" referrerpolicy=\"no-referrer\"></p><p><b>What's Next for Gilead?</b></p><p>While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p>Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.74 on $6.2 billion in revenues for the coming quarter and $7.22 on $24.94 billion in revenues for the current fiscal year.</p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Q1 Earnings Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Q1 Earnings Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 05:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-q1-earnings-212509633.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2131402534","content_text":"Gilead Sciences (GILD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.97%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $2.15 per share when it actually produced earnings of $2.19, delivering a surprise of 1.86%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.42 billion for the quarter ended March 2021, missing the Zacks Consensus Estimate by 5.30%. This compares to year-ago revenues of $5.55 billion. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Gilead shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 11.4%.Gilead Sciences shares fell 2.73% in after-hour trading.What's Next for Gilead?While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.74 on $6.2 billion in revenues for the coming quarter and $7.22 on $24.94 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":21,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}